Please assess the completion status of the following clinical trial:

Trial Title: The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced cancer patients seen in Supportive Care outpatient clinic at M.D. Anderson Cancer Center, with average sleep disturbance \>=4 out of 10 for at least one week~2. Age 18 or greater~3. Karnofsky performance status score of \>=40 at time of inclusion into study~4. Agrees to return to MD Anderson Cancer Center (MDACC) for follow-up visits~5. English speaking~Exclusion Criteria:~1. Persons with congenital blindness and self-reported acquired blindness (independent of the cause) with no light perception~2. Patients with a history of retinal disease~3. Patients with a current diagnosis of major depression disorder or generalized anxiety disorder~4. Patients who have received light therapy in the past either as part of treatment for other disorders or as a study subject~5. Patients currently on amiodarone, thiazide diuretics or epidermal growth factor receptor (EGFR) inhibitors (erlotinib, gefitinib, cetuximab, panitumumab)~6. Patients who are currently receiving ultraviolet A light/ultraviolet B light (UVA/UVB) therapy or tanning sessions at salons~7. Patients with a diagnosis of obstructive sleep apnea or narcolepsy~8. Patients with \>2 hours of direct exposure to outdoor natural light per day (light exposure diary -- screening).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bright Light Therapy (Type: EXPERIMENTAL): Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
- Dim Red Light Therapy (Type: PLACEBO_COMPARATOR): Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).